Summit Therapeutics (SMMT) Reports Q1 Loss of 6p/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Summit Therapeutics (SMMT) Reports Q1 Loss of 6p/Share

Summit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015

June 11, 2015 7:00 AM EDT

OXFORD, United Kingdom, June 11, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (Nasdaq: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and C. difficile infection ('CDI'), today reports its financial results for the three months ended 30 April 2015.

Mr Glyn Edwards, Chief Executive Officer of Summit commented: "During the first quarter, we substantially expanded our shareholder base with a successful NASDAQ listing, which has provided significant support for the on-going patient clinical trials of our... More